• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Paragon 28 Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8/8/24 4:10:55 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care
    Get the next $FNA alert in real time by email
    false 0001531978 0001531978 2024-08-05 2024-08-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): August 5, 2024

     

     

     

    Paragon 28, Inc.

    (Exact name of Registrant as Specified in its Charter)

     

     

     

    Delaware 001-40902 27-3170186

    (State or Other Jurisdiction

    of Incorporation)

    (Commission
    File Number)

    (IRS Employer

    Identification No.)

     

     

    14445 Grasslands Drive

    Englewood, Colorado

    80112  
      (Address of Principal Executive Offices) (Zip Code)  

     

    Registrant’s Telephone Number, Including Area Code: (720) 399-3400

     

    Not Applicable
    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.01 par value   FNA   The New York Stock Exchange

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 2.02 Results of Operations and Financial Condition.

     

    On August 8, 2024, Paragon 28, Inc. (“Paragon 28” or the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    The information in this Item 2.02 of this Current Report on Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), or incorporated by reference in any filing of Paragon 28 under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    (1)Effective August 5, 2024, Chadi Chahine, age 51, has been appointed as Chief Financial Officer (“CFO”) and EVP of Supply Chain Operations of Paragon 28. Mr. Chahine will become a member of the Company’s executive leadership team, reporting directly to Albert DaCosta, Chief Executive Officer and will lead all aspects of the Company’s finance function including business planning and analysis, accounting, SEC reporting, internal audit, tax, and treasury as well as its information technology and operations teams. Kristina Wright has concurrently stepped down as Interim Chief Financial Officer and will continue as a member of the Company’s Board of Directors.

     

    Mr. Chahine brings over 25 years of extensive global experience in finance and business operations, including a proven track record in the orthopedic industry. Prior to joining the Company, Mr. Chahine served as Group CFO of the Global Business Group for Zimmer Biomet Holdings Inc. (“Zimmer Biomet”), where he oversaw $7 billion in revenue and had full P&L, balance sheet, and commercial finance responsibilities, for all geographic regions. During his tenure at Zimmer Biomet, Mr. Chahine helped drive record revenue and profit in 2022 and 2023 and identified additional efficiencies in inventory and research & development investments. Prior to Zimmer Biomet, Mr. Chahine served as Chief Operating Officer and CFO of Global Stanley Security at Stanley Black & Decker prior to the business’s $4.1 billion sale. He was also previously CFO at CIRCOR International, leading takeover defense efforts and implementing significant cost-saving measures. Furthermore, he held divisional CFO roles at Smith+Nephew responsible for International Markets and the US where he led initiatives to accelerate sustainable growth. Mr. Chahine holds a Bachelor of Commerce in Accounting from Université du Québec à Montréal and a Bachelor of Science in Math and Economics from Université de Montréal.

     

    Pursuant to his Employment Agreement, Mr. Chahine will receive an annual base salary of $550,000. Mr. Chahine will receive a sign-on cash bonus of $300,000, which will be paid in $60,000 increments starting with his appointment date and thereafter every six (6) months until August 5, 2026. Mr. Chahine is also eligible to participate in the Company’s Performance Based Bonus Plan. His target performance bonus is equal to 70% of his base salary. The Company will also grant equity comprising restricted stock units (“RSUs”) and performance stock units (“PSUs”) covering a number of shares of the Company’s common stock with an aggregate value of $3,800,000, based on the thirty-day closing trading average of a share of Company common stock prior to the date of grant and rounded down the nearest whole share. The equity will be granted in accordance with the Company’s 2021 Incentive Award Plan, as amended. The RSUs will vest with respect to 25% of the RSUs on each anniversary of the date of grant, subject to Mr. Chahine’s continuing service with the Company through the applicable vesting date. The PSUs are subject to service and performance-vesting conditions and will vest following the end of the defined performance period. Each RSU and PSU represents the right to receive a share of Company common stock upon vesting.

     

     

     

     

    There are no arrangements or understandings between Mr. Chahine and any other persons pursuant to which he was appointed as an officer, and Mr. Chahine has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Mr. Chahine does not have a family relationship with any member of the Board or any executive officer of the Company.

     

    (2)Effective August 6, 2024, as part of the Company’s broader operational efficiency strategy, Albert DaCosta, Chief Executive Officer, is eliminating his salary increase and forfeiting his annual bonus for 2024. Matt Jarboe, Chief Commercial Officer, Drew Hill, EVP, Research and Development, Robert McCormack, General Counsel, Matthew Millard, Chief Human Resources Officer, and Matt Brinckman, SVP, Strategy and Investor Relations are each capping their target annual bonuses to 50%. These executives described above will have the ability to earn back the remaining 50% of their target bonus upon achievement of certain revenue and adjusted cash flow measures.

     

    Item 7.01 Regulation FD Disclosure.

     

    On August 8, 2024, the Company announced an operational efficiency strategy targeted at optimizing the organizational structure, minimizing costs and preserving cash without compromising revenue growth opportunities. This strategy was initiated in the second quarter of 2024 and is expected to result in durable savings for the rest of 2024 and in 2025. Management has determined that this operational efficiency strategy will not result in the Company incurring material charges. This operational efficiency strategy includes:

     

    ■An approximately 7% reduction in work force expected to take place in August of 2024, and is intended to result in up to $8 million in annualized savings offset by approximately $1 million in severance costs;

     

    ■Detailed review and optimization of functional costs and controls;

     

    ■An inventory burn-down plan; and

     

    ■One-time realignment of executive compensation for 2024 (as described above).

     

    On August 8, 2024, the Company posted a presentation to its website relating to the Company’s quarterly discussion of its financial profile, market strategy, products and recent developments. A copy of the presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K.

     

    The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2, shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing.

     

    Cautionary Statement Regarding Forward-Looking Statements

     

    This Current Report on Form 8-K contains certain “forward-looking” statements as that term is defined by Section 27A of the Securities Act and Section 21E of the Exchange Act. Statements that are predictive in nature, that depend on or relate to future events or conditions, or that include words such as “believes,” “anticipates,” “expects,” “may,” “will,” “would,” “should,” “estimates,” “could,” “intends,” “plans” or other similar expressions are forward-looking statements, including the Company’s preliminary financial results for the quarter ended June 30, 2024, and the Company’s operational efficiency strategy. These forward-looking statements are based on the Company’s current assumptions, expectations and beliefs and are subject to numerous risks, including, among other things, factors relating to uncertainties as to any difficulties with respect to the Company's operational efficiency strategy, including expenses associated such strategy; the effect of the announcement of the Company's operational efficiency strategy on the Company's ability to retain and hire key personnel and to maintain relationships with customers, suppliers and other business partners; risks related to the possible diversion of management’s attention as a result of the Company's operational efficiency strategy; uncertainties as to the Company's ability and the amount of time necessary to realize the expected benefits of the Company's operational efficiency strategy; and those set forth under the caption “Risk Factors” in the Company’s most recent filings with the Securities and Exchange Commission, as well as other uncertainties, assumptions and changes in circumstances that may cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied in any forward-looking statement. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this Current Report on Form 8-K.

     

     

     

     

    Further information on these and other factors that could affect the Company’s financial results and the forward-looking statements in this Current Report on Form 8-K is included in the Company’s filings with the Securities and Exchange Commission, including, among others, the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2023, particularly under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

     

    The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

     

    Item 9.01 Financial Statements and Exhibits.

     

    Exhibit
    Number
      Description of Exhibit
    99.1   Press Release, dated August 8, 2024
    99.2   Company Presentation, dated August 8, 2024
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        PARAGON 28, INC.
       
    Date: August 8, 2024 By:

    /s/ Robert S. McCormack

        General Counsel & Corporate Secretary

     

     

     

    Get the next $FNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FNA

    DatePrice TargetRatingAnalyst
    1/29/2025Buy → Hold
    Needham
    1/29/2025Outperform → Mkt Perform
    William Blair
    9/29/2023Outperform
    William Blair
    4/11/2023$23.00Overweight
    Stephens
    12/14/2022$32.00Buy
    B. Riley Securities
    3/9/2022$30.00 → $25.00Buy
    B of A Securities
    3/9/2022$25.00 → $23.00Buy
    Canaccord Genuity
    2/9/2022$31.00 → $25.00Buy
    Needham
    More analyst ratings

    $FNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Dacosta Albert returned 11,753,724 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Paragon 28, Inc. (0001531978) (Issuer)

    4/21/25 5:00:07 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    Director Wright Kristina returned 32,118 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Paragon 28, Inc. (0001531978) (Issuer)

    4/21/25 5:00:10 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Jarboe Matthew returned 575,320 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Paragon 28, Inc. (0001531978) (Issuer)

    4/21/25 5:00:14 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    $FNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Paragon 28 to Showcase Recent Product Launches at The American College of Foot and Ankle Surgeons Annual Conference

    Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference. From March 27-29, Paragon 28 will feature a suite of recently launched products designed to improve foot and ankle patient outcomes and surgeon experience. "We are thrilled to engage with foot and ankle specialists at ACFAS and showcase our latest innovations after an incredibly strong product launch cadence in 2024," said Albert DaCosta, CEO of Paragon 28. "Our progress and innovation in the space is a testament to our mission to continuous

    3/24/25 4:05:00 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    Paragon 28 Announces Expiration of HSR Act Waiting Period for Pending Acquisition by Zimmer Biomet Under HSR Act

    Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") in connection with the previously announced acquisition of Paragon 28 by Zimmer Biomet Holdings, Inc. (NYSE:ZBH) ("Zimmer Biomet"). The expiration of the waiting period under the HSR Act represents a significant milestone in the regulatory approval process, satisfying one of the conditions required to complete the proposed merger with Zimmer Biomet. With the HSR Act waiting period expired, the transaction now re

    3/11/25 4:01:00 PM ET
    $FNA
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    Paragon 28 to Feature Several Recent Product Launches at The American Academy of Orthopaedic Surgeons Annual Conference

    Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American Academy of Orthopaedic Surgeons ("AAOS"). From March 10th – 14th, Paragon 28 will feature a suite of recently launched products intended to enhance patient outcomes and the surgeon experience, including: SMART 28℠ Case Management Portal featuring SMART Bun-Yo-Matic℠ Digital case management platform designed to streamline surgical planning and execution, integrating AI, data analytics, and 3D modeling​. Provides an intuitive interface for case scheduling, direct communication with engineers, and conversion o

    3/7/25 4:32:00 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    $FNA
    SEC Filings

    View All

    SEC Form S-8 POS filed by Paragon 28 Inc.

    S-8 POS - Paragon 28, Inc. (0001531978) (Filer)

    4/21/25 4:24:46 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Paragon 28 Inc.

    S-8 POS - Paragon 28, Inc. (0001531978) (Filer)

    4/21/25 4:23:46 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Paragon 28 Inc.

    S-8 POS - Paragon 28, Inc. (0001531978) (Filer)

    4/21/25 4:22:43 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    $FNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Dacosta Albert bought $255,226 worth of shares (28,000 units at $9.12) (SEC Form 4)

    4 - Paragon 28, Inc. (0001531978) (Issuer)

    3/18/24 5:34:02 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    Dacosta Albert bought $259,555 worth of shares (30,500 units at $8.51) (SEC Form 4)

    4 - Paragon 28, Inc. (0001531978) (Issuer)

    11/13/23 8:00:07 AM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    $FNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Paragon 28 downgraded by Needham

    Needham downgraded Paragon 28 from Buy to Hold

    1/29/25 2:02:26 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    Paragon 28 downgraded by William Blair

    William Blair downgraded Paragon 28 from Outperform to Mkt Perform

    1/29/25 7:36:30 AM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    William Blair initiated coverage on Paragon 28

    William Blair initiated coverage of Paragon 28 with a rating of Outperform

    9/29/23 7:20:32 AM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    $FNA
    Leadership Updates

    Live Leadership Updates

    View All

    Paragon 28 Appoints Dave Demski to Board of Directors

    Paragon 28, Inc. (NYSE:FNA), (the "Company") a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its strategic oversight and governance capabilities. Mr. Demski most recently served as the President and CEO of Globus Medical from August 2017 to April 2022, guiding the organization through a period of signifi

    12/11/24 9:00:00 AM ET
    $ATEC
    $FNA
    Medical/Dental Instruments
    Health Care

    Appointment of Stephen M. Deitsch as new Chief Financial Officer

    OXFORD, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- OrganOx, a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking normothermic machine perfusion technology, today announces that Stephen (Steve) M. Deitsch will be joining OrganOx as Chief Financial Officer ("CFO") on April 8, 2024. Steve joins OrganOx from Paragon 28 (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopaedic market, where he has held the role of CFO since September 2020. Steve's leadership was instrumental in Paragon 28's successful IPO on the NYSE in the fall of 2021. Prior to Paragon 28, Steve held CFO r

    4/4/24 11:43:23 AM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    Paragon 28 Announces Appointment of Meghan Scanlon to Board of Directors

    Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the appointment of Meghan Scanlon to its Board of Directors. Ms. Scanlon has joined the Board's Compensation and Quality, Technology and Regulatory Committees. Ms. Scanlon has more than 20 years of senior leadership experience with global medical device companies. She currently serves as senior vice president and president, Urology and Pelvic Health, for Boston Scientific Corporation and is a member of the Boston Scientific Executive Committee. Ms. Scanlon also is a member of the Boston Scientific Global Council for Inclusion, serving as the executive sp

    3/28/22 4:02:00 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    $FNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Paragon 28 Inc.

    SC 13G - Paragon 28, Inc. (0001531978) (Subject)

    8/9/24 9:02:32 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Paragon 28 Inc. (Amendment)

    SC 13G/A - Paragon 28, Inc. (0001531978) (Subject)

    2/14/24 3:29:50 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Paragon 28 Inc. (Amendment)

    SC 13G/A - Paragon 28, Inc. (0001531978) (Subject)

    2/13/24 4:23:50 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    $FNA
    Financials

    Live finance-specific insights

    View All

    Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results

    Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basisFourth quarter diluted earnings per share were $1.20; adjusted1 diluted earnings per share were $2.31Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency1 basisFull-year diluted earnings per share were $4.43; adjusted1 diluted earnings per share were $8.00Company provides full-year 2025 financial guidanceWARSAW, Ind., Feb. 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2024.  The Company reported fourth quarter net sales of $2.023 billion, an increase of 4.3% over

    2/6/25 6:30:00 AM ET
    $FNA
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    Paragon 28 Reports Third Quarter 2024 Financial Results and Raises 2024 Net Revenue Guidance

    Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2024 and raised its 2024 net revenue guidance. Recent Business Updates Recorded global net revenue of $62.3 million in the third quarter, representing 18.1% and 17.6% reported and constant currency growth compared to the prior year period, respectively Raised net revenue guidance to $252 million to $256 million for full year 2024 net revenue, representing 16.5% to 18.3% reported growth compared to 2023 Drove a 969 basis point improvement in operating expense as a

    11/12/24 4:05:00 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    Paragon 28 To Report Third Quarter 2024 Financial Results on November 12, 2024

    Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 12, 2024. The Company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 725499. Live audio of the webcast will be available on the "Investors" section of the Company's website at: ir.paragon28.com. The

    10/17/24 4:05:00 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care